Literature DB >> 23918242

p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma.

Radoslav Davidović1, Jelena Sopta, Vesna Mandušić, Milena Krajnović, Maja Stanojević, Goran Tulić, Bogomir Dimitrijević.   

Abstract

Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16 (INK4a) /p14 (ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14 (ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14 (ARF) promoter. The results from the current study suggest significant impact of the p14 (ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918242     DOI: 10.1007/s12032-013-0682-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

Review 1.  p16(MTS-1/CDKN2/INK4a) in cancer progression.

Authors:  J W Rocco; D Sidransky
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 2.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

3.  Reciprocal relationship between methylation status and loss of heterozygosity at the p14(ARF) locus in Australian and South African hepatocellular carcinomas.

Authors:  Nirmitha I Herath; Michael C Kew; Michael D Walsh; Joanne Young; Lawrie W Powell; Barbara A Leggett; Graeme A MacDonald
Journal:  J Gastroenterol Hepatol       Date:  2002-03       Impact factor: 4.029

4.  Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.

Authors:  Gaëlle Pérot; Frédéric Chibon; Audrey Montero; Pauline Lagarde; Hugues de Thé; Philippe Terrier; Louis Guillou; Dominique Ranchère; Jean-Michel Coindre; Alain Aurias
Journal:  Am J Pathol       Date:  2010-10       Impact factor: 4.307

5.  Alterations and hypermethylation of the p14(ARF) gene in gastric cancer.

Authors:  S Iida; Y Akiyama; T Nakajima; W Ichikawa; Z Nihei; K Sugihara; Y Yuasa
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

Review 6.  Cyclin-dependent kinase pathways as targets for cancer treatment.

Authors:  Geoffrey I Shapiro
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

7.  Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors.

Authors:  S Zheng; P Chen; A McMillan; A Lafuente; M J Lafuente; A Ballesta; M Trias; J K Wiencke
Journal:  Carcinogenesis       Date:  2000-11       Impact factor: 4.944

8.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

Review 9.  Molecular pathology of sarcomas.

Authors:  Daniel Osuna; Enrique de Alava
Journal:  Rev Recent Clin Trials       Date:  2009-01

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  4 in total

Review 1.  Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

Authors:  Alessandro De Vita; Laura Mercatali; Federica Recine; Federica Pieri; Nada Riva; Alberto Bongiovanni; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

Review 2.  Clinical and Molecular Spectrum of Liposarcoma.

Authors:  Alex Thomas John Lee; Khin Thway; Paul H Huang; Robin Lewis Jones
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

Review 3.  Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.

Authors:  Pere Llinàs-Arias; Manel Esteller
Journal:  Open Biol       Date:  2017-09       Impact factor: 6.411

4.  MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma.

Authors:  Melissa Vos; Ruben Boers; Anne L M Vriends; Joachim Boers; Patricia F van Kuijk; Winan J van Houdt; Geert J L H van Leenders; Michal Wagrodzki; Wilfred F J van IJcken; Joost Gribnau; Dirk J Grünhagen; Cornelis Verhoef; Stefan Sleijfer; Erik A C Wiemer
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.